XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information 3 (Detail) (USD $)
 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2014
Dec. 31, 2013
Sep. 30, 2012
Second Right to Develop Collaboration [Member]
Sep. 30, 2014
Second Right to Develop Collaboration [Member]
Sep. 30, 2014
Servier [Member]
Nov. 30, 2011
Servier [Member]
Sep. 30, 2014
Servier [Member]
Sep. 30, 2013
Servier [Member]
Sep. 30, 2014
Servier [Member]
Sep. 30, 2013
Servier [Member]
Dec. 31, 2013
Servier [Member]
Sep. 30, 2014
Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2014
Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2014
Servier [Member]
Scenario, Adjustment [Member]
Sep. 30, 2014
Servier [Member]
Maximum [Member]
Sep. 30, 2014
Servier [Member]
Maximum [Member]
Second Right to Develop Collaboration [Member]
License And Collaboration Agreements [Line Items]                                      
Collaboration agreement date                 November 2011         September 2012          
Non-refundable payment     $ 20,000,000     $ 20,000,000                          
Additional license grant fees                                   30,000,000 65,000,000
Clinical milestone payments                                   47,000,000 98,000,000
Regulatory milestone payments                                   140,000,000 300,000,000
Sales milestone payments                                   208,000,000 630,000,000
Expected period of development         42 months       27 months     75 months   29 months     38 months    
Recognized revenue under agreement             200,000 12,300,000 600,000 18,900,000   5,800,000 2,200,000 15,900,000 6,500,000        
Milestone payment               10,000,000   10,000,000     0   0        
Deferred revenue         300,000   300,000   300,000   900,000 18,500,000   18,500,000   9,400,000      
Clinical milestone payments under agreement                                     5,000,000
License option fees received                           15,000,000          
Clinical milestone payments received under agreement       5,000,000                   10,000,000          
Offset to research and development costs under collaboration arrangement                       400,000   800,000          
Expected development period                           82 months          
Clinical milestone payments under agreement                       5,000,000   5,000,000          
Review period       30 days                              
Deferred revenue included in current liabilities 15,617,000 20,267,000                   3,300,000   3,300,000   8,600,000      
Deferred revenue included in long-term liabilities $ 19,052,000 $ 7,136,000                   $ 15,200,000   $ 15,200,000   $ 800,000